{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:11:39Z","timestamp":1792789899697,"version":"4.5.0"},"reference-count":68,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n The net benefit of oral anticoagulants (OACs) in patients with atrial fibrillation (AF) and advanced chronic kidney disease (CKD) not receiving dialysis remains uncertain.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare the estimated effectiveness and safety of apixaban compared with warfarin and no OAC use among patients with AF and advanced CKD not receiving dialysis.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This retrospective cohort study used a 3-group target trial emulation framework and included patients from Medicare fee-for-service claims (January 1, 2013, to December 31, 2022) and the Optum deidentified Clinformatics Data Mart database (January 1, 2013, to February 28, 2025). Eligible participants had AF, CKD stage 4 or 5, no prior dialysis, and continuous medical and pharmacy coverage. Data analysis was conducted from February 2025 to June 2026.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Initiation of apixaban or warfarin vs no oral anticoagulation.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Primary outcomes were hospitalization for major bleeding, ischemic stroke, and their composite. Propensity score matching weights were used to balance baseline characteristics, and weighted hazard ratios (HRs) and rate differences (RDs) per 1000 person-years (PYs) were estimated.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The study included 14\u202f712 apixaban users (7954 female [54.1%]; mean [SD] age, 78.93 [7.35] years), 6335 warfarin users (3148 female [49.7%]; mean [SD] age, 77.47 [7.03] years), and 21\u202f005 nonusers of OACs (10\u202f797 female [51.4%]; mean [SD] age, 79.59 [7.49] years). Compared with nonusers, apixaban was associated with an increased rate of major bleeding (HR, 1.32 [95% CI, 1.11 to 1.58]; RD, 17.16 [95% CI, 2.45 to 31.87] per 1000 PYs) and a lower rate of ischemic stroke (HR, 0.46 [95% CI, 0.32 to 0.66]; RD, \u221212.67 [95% CI, \u221220.65 to \u22124.69] per 1000 PYs), but there was no association with the composite outcome (HR, 1.05 [95% CI, 0.89 to 1.22]; RD, 6.13 [95% CI, \u221210.61 to 22.87] per 1000 PYs). Warfarin users had a higher rate of major bleeding (HR, 2.44 [95% CI, 2.06 to 2.88]) and no significant diffrence in the rate of ischemic stroke (HR, 0.87 [95% CI, 0.61 to 1.22]), resulting in a higher rate of the composite outcome compared with nonuse (HR, 1.95 [95% CI, 1.69 to 2.26]). Compared with warfarin, apixaban was associated with lower risk of major bleeding (HR, 0.55 [95% CI, 0.46 to 0.65]) and ischemic stroke (HR, 0.50 [95% CI, 0.33 to 0.78]).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This study found that among patients with AF and advanced CKD not receiving dialysis, anticoagulation was associated with reduced risk of ischemic stroke, but increased risk of bleeding compared with nonuse, suggesting that the trade-off between ischemic stroke reduction and bleeding risk was more favorable for apixaban than for warfarin.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.32225","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:37:10Z","timestamp":1788536230000},"page":"e2632225","source":"Crossref","is-referenced-by-count":2,"title":["Oral Anticoagulants in Patients With Atrial Fibrillation and Advanced CKD Not Requiring Dialysis"],"prefix":"10.1001","volume":"9","author":[{"given":"Qiaoxi","family":"Chen","sequence":"first","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Singer","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts"},{"name":"Department of Medicine, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edouard L.","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Ting","family":"Yang","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Pritchard","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi J.","family":"Desai","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kueiyu Joshua","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"},{"name":"Division of General Internal Medicine, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"issue":"8","key":"zoi260885r1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.27753","article-title":"Atrial fibrillation in chronic kidney disease: an overview.","volume":"14","author":"Gadde","year":"2022","journal-title":"Cureus"},{"issue":"8","key":"zoi260885r2","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1002\/clc.23196","article-title":"Anticoagulation in chronic kidney disease: from guidelines to clinical practice.","volume":"42","author":"Aursulesei","year":"2019","journal-title":"Clin Cardiol"},{"issue":"17","key":"zoi260885r3","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1001\/jama.298.17.2038","article-title":"Prevalence of chronic kidney disease in the United States.","volume":"298","author":"Coresh","year":"2007","journal-title":"JAMA"},{"issue":"3","key":"zoi260885r4","doi-asserted-by":"publisher","first-page":"A7","DOI":"10.1053\/j.ajkd.2019.01.001","article-title":"US Renal Data System 2018 annual data report: epidemiology of kidney disease in the United States.","volume":"73","author":"Saran","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"zoi260885r5","doi-asserted-by":"publisher","first-page":"A7","DOI":"10.1053\/j.ajkd.2016.12.004","article-title":"US Renal Data System 2016 annual data report: epidemiology of kidney disease in the United States.","volume":"69","author":"Saran","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"zoi260885r6","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1001\/archinternmed.2012.121","article-title":"Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis.","volume":"172","author":"Agarwal","year":"2012","journal-title":"Arch Intern Med"},{"issue":"9586","key":"zoi260885r7","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S0140-6736(07)61233-1","article-title":"Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial.","volume":"370","author":"Mant","year":"2007","journal-title":"Lancet"},{"issue":"12","key":"zoi260885r8","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation.","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"issue":"9","key":"zoi260885r9","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation.","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"issue":"10","key":"zoi260885r10","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"issue":"22","key":"zoi260885r11","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation.","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"zoi260885r12","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.003725","article-title":"Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation.","volume":"5","author":"Yao","year":"2016","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"zoi260885r13","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation.","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"17","key":"zoi260885r14","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1161\/CIRCULATIONAHA.119.044059","article-title":"Apixaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease.","volume":"141","author":"Stanifer","year":"2020","journal-title":"Circulation"},{"issue":"17","key":"zoi260885r15","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1016\/j.jacc.2019.08.1031","article-title":"Anticoagulation in concomitant chronic kidney disease and atrial fibrillation: JACC review topic of the week.","volume":"74","author":"Kumar","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"zoi260885r16","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1053\/j.ajkd.2013.02.381","article-title":"Atrial fibrillation in CKD: balancing the risks and benefits of anticoagulation.","volume":"62","author":"Ng","year":"2013","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"zoi260885r17","doi-asserted-by":"publisher","first-page":"181","DOI":"10.7326\/M19-0087","article-title":"Benefits and harms of oral anticoagulant therapy in chronic kidney disease: a systematic review and meta-analysis.","volume":"171","author":"Ha","year":"2019","journal-title":"Ann Intern Med"},{"issue":"3","key":"zoi260885r18","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1053\/j.ajkd.2023.08.017","article-title":"Comparative safety and effectiveness of warfarin or rivaroxaban versus apixaban in patients with advanced CKD and atrial fibrillation: nationwide US cohort study.","volume":"83","author":"Fu","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"zoi260885r19","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac544.2712","article-title":"Oral anticoagulation in patients with atrial fibrillation and stage IV and V chronic kidney disease: a systematic review and meta-analysis.","volume":"43","author":"Miranda-Arboleda","year":"2022","journal-title":"Eur Heart J"},{"issue":"9","key":"zoi260885r20","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.34067\/KID.0000000809","article-title":"Safety and effectiveness of apixaban versus warfarin by kidney function in atrial fibrillation: a binational population-based study.","volume":"6","author":"Lam","year":"2025","journal-title":"Kidney360"},{"issue":"5","key":"zoi260885r21","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.mayocp.2023.01.007","article-title":"Oral anticoagulation in patients with advanced chronic kidney disease and atrial fibrillation: beyond anticoagulation.","volume":"98","author":"Dhaese","year":"2023","journal-title":"Mayo Clin Proc"},{"issue":"21","key":"zoi260885r22","doi-asserted-by":"publisher","first-page":"e2421","DOI":"10.1212\/WNL.0000000000007534","article-title":"Oral anticoagulation in patients with chronic kidney disease: a systematic review and meta-analysis.","volume":"92","author":"Malhotra","year":"2019","journal-title":"Neurology"},{"key":"zoi260885r23","doi-asserted-by":"publisher","first-page":"5583","DOI":"10.1182\/blood-2024-212201","article-title":"Comparing the efficacy and safety of apixaban and warfarin in patients with atrial fibrillation and advanced chronic kidney disease.","volume":"144","author":"Ali Asgar","year":"2024","journal-title":"Blood"},{"issue":"2","key":"zoi260885r24","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","article-title":"2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons.","volume":"140","author":"January","year":"2019","journal-title":"Circulation"},{"issue":"16","key":"zoi260885r25","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"issue":"10","key":"zoi260885r26","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.cjca.2014.08.001","article-title":"2014 focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation.","volume":"30","author":"Verma","year":"2014","journal-title":"Can J Cardiol"},{"issue":"2","key":"zoi260885r27","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC).","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"issue":"38","key":"zoi260885r28","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS.","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"issue":"5","key":"zoi260885r29","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.chest.2018.07.040","article-title":"Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report.","volume":"154","author":"Lip","year":"2018","journal-title":"Chest"},{"issue":"24","key":"zoi260885r30","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1093\/eurheartj\/ehy060","article-title":"Chronic kidney disease and arrhythmias: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference.","volume":"39","author":"Turakhia","year":"2018","journal-title":"Eur Heart J"},{"issue":"16","key":"zoi260885r31","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1001\/jama.2023.4221","article-title":"Emulation of randomized clinical trials with nonrandomized database analyses: results of 32 clinical trials.","volume":"329","author":"Wang","year":"2023","journal-title":"JAMA"},{"issue":"24","key":"zoi260885r32","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1001\/jama.2022.21383","article-title":"Target trial emulation: a framework for causal inference from observational data.","volume":"328","author":"Hern\u00e1n","year":"2022","journal-title":"JAMA"},{"issue":"1","key":"zoi260885r33","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1471-2288-11-25","article-title":"Validation of a case definition to define chronic dialysis using outpatient administrative data.","volume":"11","author":"Clement","year":"2011","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"zoi260885r34","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12911-020-01206-x","article-title":"Developing and validating an algorithm to identify incident chronic dialysis patients using administrative data.","volume":"20","author":"Gibertoni","year":"2020","journal-title":"BMC Med Inform Decis Mak"},{"key":"zoi260885r35","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2025-084909","article-title":"Starting right: aligning eligibility and treatment assignment at time zero when emulating a target trial.","volume":"392","author":"Fu","year":"2026","journal-title":"BMJ"},{"issue":"12","key":"zoi260885r36","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1093\/eurheartj\/ehr488","article-title":"Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182?678 patients with atrial fibrillation: the Swedish atrial fibrillation cohort study.","volume":"33","author":"Friberg","year":"2012","journal-title":"Eur Heart J"},{"issue":"2","key":"zoi260885r37","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation.","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"issue":"6","key":"zoi260885r38","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/pds.2109","article-title":"An automated database case definition for serious bleeding related to oral anticoagulant use.","volume":"20","author":"Cunningham","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"zoi260885r39","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1161\/01.STR.0000032240.28636.BD","article-title":"Validating administrative data in stroke research.","volume":"33","author":"Tirschwell","year":"2002","journal-title":"Stroke"},{"issue":"1","key":"zoi260885r40","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/pds.1518","article-title":"Validation of ICD-9 codes with a high positive predictive value for incident strokes resulting in hospitalization using Medicaid health data.","volume":"17","author":"Roumie","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"zoi260885r41","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jacc.2010.09.024","article-title":"Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (hypertension, abnormal renal\/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs\/alcohol concomitantly) score.","volume":"57","author":"Lip","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"zoi260885r42","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.jclinepi.2010.10.004","article-title":"A combined comorbidity score predicted mortality in elderly patients better than existing scores.","volume":"64","author":"Gagne","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"zoi260885r43","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1093\/gerona\/glx229","article-title":"Measuring frailty in Medicare data: development and validation of a claims-based frailty index.","volume":"73","author":"Kim","year":"2018","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"8","key":"zoi260885r44","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1093\/gerona\/gly197","article-title":"Validation of a claims-based frailty index against physical performance and adverse health outcomes in the health and retirement study.","volume":"74","author":"Kim","year":"2019","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"zoi260885r45","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l5657","article-title":"Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners.","author":"Desai","year":"2019","journal-title":"BMJ"},{"issue":"9","key":"zoi260885r47","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.jacc.2016.11.075","article-title":"Reply: apixaban dosing in chronic kidney disease: differences between U.S. and E.U. labeling.","volume":"69","author":"Proietti","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"zoi260885r48","doi-asserted-by":"publisher","first-page":"7423","DOI":"10.3390\/jcm11247423","article-title":"Oral anticoagulant use and appropriateness in elderly patients with atrial fibrillation in complex clinical conditions: ACONVENIENCE study.","volume":"11","author":"Bonanad","year":"2022","journal-title":"J Clin Med"},{"issue":"4","key":"zoi260885r49","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1097\/EDE.0b013e3181a663cc","article-title":"High-dimensional propensity score adjustment in studies of treatment effects using health care claims data.","volume":"20","author":"Schneeweiss","year":"2009","journal-title":"Epidemiology"},{"issue":"5","key":"zoi260885r50","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1080\/10543406.2020.1757692","article-title":"The inverse-probability-of-censoring weighting (IPCW) adjusted win ratio statistic: an unbiased estimator in the presence of independent censoring.","volume":"30","author":"Dong","year":"2020","journal-title":"J Biopharm Stat"},{"issue":"4","key":"zoi260885r51","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.kint.2016.11.028","article-title":"Anticoagulation, atrial fibrillation, and chronic kidney disease\u2014whose side are you on?","volume":"91","author":"Heine","year":"2017","journal-title":"Kidney Int"},{"issue":"13","key":"zoi260885r52","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1016\/j.jacep.2020.06.036","article-title":"Clinical outcomes of Warfarin initiation in advanced chronic kidney disease patients with incident atrial fibrillation.","volume":"6","author":"Agarwal","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"issue":"3","key":"zoi260885r53","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1080\/14740338.2025.2574492","article-title":"Safety and efficacy of anticoagulant administration in people with atrial fibrillation and advanced chronic kidney disease.","volume":"25","author":"Irlik","year":"2026","journal-title":"Expert Opin Drug Saf"},{"issue":"11","key":"zoi260885r54","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.amjmed.2019.06.006","article-title":"Efficacy and safety of oral anticoagulants in patients with atrial fibrillation and stages 4 or 5 chronic kidney disease.","volume":"132","author":"Chang","year":"2019","journal-title":"Am J Med"},{"issue":"3","key":"zoi260885r55","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.ekir.2022.12.002","article-title":"Association of kidney function with risk of adverse effects of therapies for atrial fibrillation.","volume":"8","author":"Bansal","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"4","key":"zoi260885r56","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1378\/chest.15-1719","article-title":"Stroke, major bleeding, and mortality outcomes in warfarin users with atrial fibrillation and chronic kidney disease: a meta-analysis of observational studies.","volume":"149","author":"Dahal","year":"2016","journal-title":"Chest"},{"issue":"3","key":"zoi260885r57","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1053\/j.ajkd.2025.10.009","article-title":"Effectiveness and safety of apixaban initiation following newly-diagnosed atrial fibrillation in patients with kidney failure on hemodialysis.","volume":"87","author":"Winkelmayer","year":"2026","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"zoi260885r58","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.30230","article-title":"Safety and efficacy of apixaban vs warfarin in patients with stage 4 and 5 chronic kidney disease: a systematic review.","volume":"14","author":"Fatima","year":"2022","journal-title":"Cureus"},{"issue":"23","key":"zoi260885r59","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1016\/j.jacc.2017.03.600","article-title":"Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction.","volume":"69","author":"Yao","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"zoi260885r60","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.752468","article-title":"Apixaban vs. warfarin in atrial fibrillation patients with chronic kidney disease.","volume":"8","author":"Fu","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"12","key":"zoi260885r61","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1212\/WNL.0000000000000248","article-title":"Long-term survival after ischemic stroke in patients with atrial fibrillation.","volume":"82","author":"Fang","year":"2014","journal-title":"Neurology"},{"issue":"7","key":"zoi260885r62","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1161\/STROKEAHA.111.630731","article-title":"Thirty-day mortality after ischemic stroke and intracranial hemorrhage in patients with atrial fibrillation on and off anticoagulants.","volume":"43","author":"Fang","year":"2012","journal-title":"Stroke"},{"issue":"11","key":"zoi260885r63","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.119.006212","article-title":"Net clinical benefit of oral anticoagulation among older adults with atrial fibrillation.","volume":"12","author":"Shah","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"6","key":"zoi260885r64","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1161\/CIRCOUTCOMES.114.001013","article-title":"Patients\u2019 preferences in anticoagulant therapy: discrete choice experiment.","volume":"7","author":"Najafzadeh","year":"2014","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"7323","key":"zoi260885r65","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1136\/bmj.323.7323.1218","article-title":"Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study.","volume":"323","author":"Devereaux","year":"2001","journal-title":"BMJ"},{"key":"zoi260885r66","doi-asserted-by":"publisher","first-page":"e601S","DOI":"10.1378\/chest.11-2302","article-title":"Antithrombotic and thrombolytic therapy for ischemic stroke: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines.","volume":"141","author":"Lansberg","year":"2012","journal-title":"Chest"},{"issue":"11","key":"zoi260885r67","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1161\/CIRCULATIONAHA.114.014113","article-title":"Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.","volume":"131","author":"Chan","year":"2015","journal-title":"Circulation"},{"issue":"11","key":"zoi260885r68","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s40261-018-0693-6","article-title":"Safety of edoxaban 30 mg in elderly patients with severe renal impairment.","volume":"38","author":"Fazio","year":"2018","journal-title":"Clin Drug Investig"},{"key":"zoi260885r46","unstructured":"European Medicines Agency. Eliquis: summary of product characteristics. Published June 20, 2011. Updated October 4, 2026. Accessed July 24, 2026. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/eliquis"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2853785\/chen_2026_oi_260885_1790795968.56119.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:00:29Z","timestamp":1791298829000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2853785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":68,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.32225","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]}}}